HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baudin, E. Articles by Parmentier, C. Search for Related Content PubMed PubMed Citation Articles by Baudin, E. Articles by Parmentier, C.

Comparison of Octreotide Scintigraphy and Conventional Imaging in Medullary Thyroid Carcinoma

Departments of Nuclear Medicine, Radiology and Surgery, Institut Gustave Roussy, Villejuif, France

Correspondence: For correspondence or reprints contact: M. Schlumberger, MD, Nuclear Service, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France.

ABSTRACT

We evaluated the clinical utility of positive somatostatin receptor scintigraphy in patients with medullary thyroid cancer (MTC). Methods: Twenty-four MTC patients with increased calcitonin levels underwent somatostatin receptor scintigraphy using ¹¹¹In-pentetreotide (120–200 MBq) with early (4 hr after injection) and delayed (24 hr) whole-body scans and liver SPECT imaging. In Group 1 (12 patients), conventional imaging modalities demonstrated the presence of tumor sites prior to somatostatin receptor scintigraphy; in Group 2 (12 patients), conventional imaging modalities were negative or inconclusive. Results: Somatostatin receptor scintigraphy had positive results in 9 of 24 patients (37%): of Group 1 patients, 7 of 12 had positive somatostatin receptor scintigraphy results. Of these patients cases, somatostatin receptor scintigraphy demonstrated several involved organs and tumor sites either identical (two patients) or smaller (five patients) in size than conventional imaging modalities. Only two patients in Group 2 had positive somatostatin receptor scintigraphy results which demonstrated significant mediastinal uptake previously classified as indeterminate on conventional imaging modalities. No new tumor site was identified nor were therapeutic options modified by the somatostatin receptor scintigraphy results. Conclusion: Somatostatin receptor scintigraphy only demonstrates part of tumor sites and cannot visualize small tumor sites (1 cm). We believe that somatostatin receptor scintigraphy has a limited role in the management of MTC patients.

Key Words: medullary thyroid carcinoma • indium-111-octreotide • scintigraphy

This article has been cited by other articles:

				A. L. Giraudet, D. Vanel, S. Leboulleux, A. Auperin, C. Dromain, L. Chami, N. Ny Tovo, J. Lumbroso, N. Lassau, G. Bonniaud, et al. Imaging Medullary Thyroid Carcinoma with Persistent Elevated Calcitonin Levels J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4185 - 4190. [Abstract] [Full Text] [PDF]

				K. Pacak, I. Ilias, C. C. Chen, J. A. Carrasquillo, M. Whatley, and L. K. Nieman The Role of [18F]Fluorodeoxyglucose Positron Emission Tomography and [111In]-Diethylenetriaminepentaacetate-D-Phe-Pentetreotide Scintigraphy in the Localization of Ectopic Adrenocorticotropin-Secreting Tumors Causing Cushing's Syndrome J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2214 - 2221. [Abstract] [Full Text] [PDF]

				S. Szakall Jr., O. Esik, G. Bajzik, I. Repa, G. Dabasi, I. Sinkovics, P. Agoston, and L. Tron 18F-FDG PET Detection of Lymph Node Metastases in Medullary Thyroid Carcinoma J. Nucl. Med., January 1, 2002; 43(1): 66 - 71. [Abstract] [Full Text] [PDF]

				B. Wangberg, O. Nilsson, V. Johanson, L. Kolby, E. Forssell-Aronsson, P. Andersson, M. Fjalling, L.-E. Tisell, and H. Ahlman Somatostatin Receptors in the Diagnosis and Therapy of Neuroendocrine Tumors Oncologist, February 1, 1997; 2(1): 50 - 58. [Abstract] [Full Text] [PDF]